Pig NGAL ELISA Kit (KIT 044)
Early kidney injury detection has been long sought and NGAL has recently been shown to be the biomarker that could fill this diagnostic gap. Measured from baseline, NGAL levels rise significantly in both urine and blood as a response to kidney injury – nephrotoxic, ischemic or otherwise. The pig is an often used
experimental model for medical research because of its close resemblance to humans. Pigs are being used in everything from experimental treatments to experimental surgical procedures.
The pharmaceutical industry is also looking more and more to pigs as a model for drug safety assessment in drug development as pigs are claimed to be more robust than the traditional dog models and in some cases a better mirror model of humans than dogs or even monkeys. Pigs are most often being used for pharmaceutical toxicology in Europe but number of pig experiments on the Americanand other markets are rising rapidly.
The NGAL Test
BioPorto Diagnostics has successfully developed The NGAL Test for the diagnosis of acute kidney injury. The NGAL test is designed for routine diagnostic use on a wide range of automated clinical chemistry analyzers that are already running in laboratories and hospitals all over the world.
Like the majority of other high volume routine biomarkers the new NGAL test from BioPorto is based on the principle of turbidimetry, recognized to combine high diagnostic performance with fast turnaround time and therefore implicitly addressing the acute aspect of NGAL evaluation.
For more information about The NGAL Test, please contact Klaus Boberg Pedersen, Product Manager, Human Diagnostics, at kbp@bioporto.com.
Unique product: APC-PCI ELISA Kit (KIT 040)
The APC-PCI (Activated Protein C - Protein C Inhibitor) complex is formed in blood circulation upon activation of protein C. APC is then inactivated by PCI forming an inhibition complex known as the APC-PCI complex.
The APC-PCI ELISA Kit (KIT 040) is intended for the measurement of the Activated Protein C - Protein C Inhibitor complex in human plasma. It is for research use only. Not for use in diagnostic procedures.
Further expansion of our GLP-1 portfolio
The new antibody ABS 046-03 recognizes the C-terminus of non-amidated (-Arg-Gly) GLP-1 (GLP-1(1-37), GLP-1(7-37) and GLP-1(9-37)) and shows a low level of cross-reactivity with C-terminally amidated GLP-1 (GLP-1(1-36)amide, GLP-1(7-36)amide and GLP-1(9-36)amide).
Two different sandwich setups can be made using different combinations of ABS 046-03, HYB 147-12 and ABS 033-10.
Ghrelin antibodies: expansion of the peptide hormone antibody portfolio
The launch of two new anti-ghrelin antibodies provides a tool for measuring total ghrelin levels in human sample. The two antibodies are designed to work together as a sandwich antibody pair to give sensitive measurements.
BioPorto Diagnostics offers an extensive range of monoclonal antibodies within the peptide hormone area. These antibodies are widely used by researchers and pharmaceutical companies around the world. Especially in the field of obesity and type-2 diabetes, these antibodies give researchers a unique opportunity to measure relevant peptide hormones.
